A Phase 1 interventional study of Andecaliximab and Gemcitabine in Pancreatic Cancer, Non-small Cell Lung Cancer and Esophagogastric Cancer, sponsored by Gilead Sciences. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-02.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 300 open to participants now, 474 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.
Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 154th largest by enrollment of the 1,574 interventional ones that give a count, is one of 77 that started in 2013, is one of 556 in phase 1, and was the 713th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →300 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Anova Innovation Limited · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
IMGT Co., Ltd. · Sites in United States, Korea, Republic of
Ages 18–85
AdventHealth · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,851 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 778 · Phase 2 721 · Phase 3 91 · Phase 4 12
First in 1991; this study’s year is marked. 77 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 236 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 1,574 interventional studies, 137 across the 230 observational. Of the 1,219 that completed or were terminated, 478 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
577 of 1,851 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 8 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
165 of the studies in Pancreatic Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT03257033Phase 3RenovoRxIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | 2027-06 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with chemotherapy.
The study consists of 2 parts (Parts A and B). Participants can only qualify for and participate in 1 part.
Part A is a sequential dose escalation to determine the maximum tolerated dose of andecaliximab in participants with advanced solid tumors that are refractory to or intolerant to standard therapy or for which no standard therapy exists. In Part A, participants will receive andecaliximab only.
Part B is a dose expansion to obtain additional safety and tolerability data for andecaliximab in participants with advanced pancreatic adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, esophagogastric adenocarcinoma, colorectal cancer, or breast cancer. In Part B, participants will receive andecaliximab in combination with standard-of-care chemotherapy.
Key Inclusion Criteria:
Part B: Pancreatic Adenocarcinoma
Part B: NSCLC
Part B: Esophagogastric Adenocarcinoma:
Part B: Colorectal Cancer
Part B: Second-Line Colorectal Cancer
Part B: Breast Cancer
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab
Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab
Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug
Drug: Andecaliximab
Participants with PAC will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Gemcitabine · Drug: Nab-paclitaxel
Participants with lung adenocarcinoma (LAC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Carboplatin · Drug: Pemetrexed
Participants with lung squamous cell carcinoma (LSC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Carboplatin · Drug: Paclitaxel
Participants with esophagogastric adenocarcinoma (EGC) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} \[mFOLFOX6\], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Leucovorin · Drug: Oxaliplatin · Drug: 5-FU
Participants with colorectal cancer (CRC) will receive first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Leucovorin · Drug: Oxaliplatin · Drug: 5-FU · Drug: Bevacizumab
Participants with CRC will receive FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Leucovorin · Drug: Oxaliplatin · Drug: 5-FU · Drug: Bevacizumab
Participants with CRC will receive second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU \[FOLFIRI\] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Leucovorin · Drug: 5-FU · Drug: Bevacizumab · Drug: Irinotecan
Participants with CRC will receive SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Leucovorin · Drug: 5-FU · Drug: Bevacizumab · Drug: Irinotecan
Participants with breast cancer (BRCA) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Paclitaxel
Administered intravenous infusion
Also known as: GS-5745
Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
Administered intravenously on Day 1 of each 21-day treatment cycle
Administered intravenously on Day 1 of each 21-day treatment cycle
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days
Percentage of Participants Experiencing Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.
Time frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days
Participants were enrolled at study sites in the United States. The first participant was screened on 29 March 2013. The last study visit occurred on 23 April 2019.
| Milestone | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 6 | 36 | 11 | 10 | 41 | 46 | 11 | 45 | 8 | 15 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 3 | 6 | 36 | 11 | 10 | 41 | 46 | 11 | 45 | 8 | 15 |
| Withdrew: Progressive disease | 4 | 3 | 6 | 22 | 5 | 8 | 23 | 24 | 3 | 29 | 6 | 11 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 5 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 6 | 1 | 0 | 8 | 3 | 1 | 5 | 0 | 1 |
| Withdrew: Investigator's discretion | 0 | 0 | 0 | 7 | 2 | 1 | 7 | 10 | 6 | 7 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 3 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unknown reason | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Specified criteria for withdrawal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Enrolled but never treated | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| percentage of participants | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 | 100.0 | 83.3 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.
| percentage of participants | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Laboratory abnormalities: Hematology | 0.0 | 33.3 | 33.3 | 97.2 | 90.0 | 80.0 | 87.5 | 84.4 | 90.9 | 95.5 | 100.0 | 86.7 |
| Any Laboratory abnormalities: Serum Chemistry | 100.0 | 66.7 | 83.3 | 88.9 | 60.0 | 70.0 | 87.5 | 95.6 | 81.8 | 86.4 | 87.5 | 66.7 |
| Any Laboratory abnormalities: Coagulation | 25.0 | 0.0 | 33.3 | 38.9 | 10.0 | 10.0 | 35.0 | 37.8 | 36.4 | 45.5 | 37.5 | 40.0 |
Collected over Adverse Events: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days All-cause Mortality: From Study Start date (29 March 2013) up to study completion date (23 April 2019) (6 years and 1 month). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: ADX 200 mg | 1/4 (25%) | 0/4 (0%) | 4/4 (100%) |
| Part A: ADX 600 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part A: ADX 1800 mg | 1/6 (16.7%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Part B: PAC, ADX 800 mg | 8/36 (22.2%) | 19/36 (52.8%) | 36/36 (100%) |
| Part B: LAC, ADX 1200 mg | 4/10 (40%) | 5/10 (50%) | 9/10 (90%) |
| Part B: LSC, ADX 1200 mg | 3/10 (30%) | 6/10 (60%) | 10/10 (100%) |
| Part B: EGC, ADX 800 mg | 13/40 (32.5%) | 19/40 (47.5%) | 40/40 (100%) |
| Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | 22/45 (48.9%) | 17/45 (37.8%) | 45/45 (100%) |
| Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | 5/11 (45.5%) | 3/11 (27.3%) | 11/11 (100%) |
| Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | 25/44 (56.8%) | 13/44 (29.5%) | 44/44 (100%) |
| Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | 5/8 (62.5%) | 4/8 (50%) | 8/8 (100%) |
| Part B: BRCA, ADX 800 mg | 8/15 (53.3%) | 5/15 (33.3%) | 15/15 (100%) |
| Event | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 0/6 | 0/36 | 1/10 | 2/10 | 1/40 | 1/45 | 0/11 | 0/44 | 0/8 | 0/15 |
| Duodenal obstructionGastrointestinal disorders | 0/4 | 0/3 | 1/6 | 1/36 | 0/10 | 0/10 | 0/40 | 0/45 | 0/11 | 0/44 | 0/8 | 0/15 |
| Acute kidney injuryRenal and urinary disorders | 0/4 | 0/3 | 1/6 | 2/36 | 0/10 | 0/10 | 1/40 | 1/45 | 0/11 | 0/44 | 0/8 | 1/15 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 1/6 | 0/36 | 0/10 | 0/10 | 0/40 | 0/45 | 0/11 | 0/44 | 0/8 | 0/15 |
| PyrexiaGeneral disorders | 0/4 | 0/3 | 0/6 | 5/36 | 0/10 | 0/10 | 2/40 | 0/45 | 0/11 | 0/44 | 0/8 | 0/15 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/6 | 0/36 | 0/10 | 0/10 | 1/40 | 0/45 | 0/11 | 0/44 | 1/8 | 0/15 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/3 | 0/6 | 1/36 | 1/10 | 0/10 | 2/40 | 0/45 | 0/11 | 0/44 | 1/8 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/3 | 0/6 | 2/36 | 0/10 | 1/10 | 1/40 | 0/45 | 0/11 | 0/44 | 1/8 | 0/15 |
| Large intestinal obstructionGastrointestinal disorders | 0/4 | 0/3 | 0/6 | 0/36 | 0/10 | 0/10 | 0/40 | 0/45 | 0/11 | 1/44 | 1/8 | 0/15 |
| CellulitisInfections and infestations | 0/4 | 0/3 | 0/6 | 3/36 | 0/10 | 0/10 | 0/40 | 1/45 | 0/11 | 0/44 | 1/8 | 0/15 |
| Event | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/4 | 2/3 | 2/6 | 18/36 | 3/10 | 5/10 | 25/40 | 33/45 | 9/11 | 27/44 | 5/8 | 6/15 |
| FatigueGeneral disorders | 2/4 | 2/3 | 0/6 | 27/36 | 5/10 | 7/10 | 23/40 | 36/45 | 7/11 | 26/44 | 6/8 | 11/15 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 0/3 | 0/6 | 16/36 | 4/10 | 2/10 | 19/40 | 25/45 | 3/11 | 28/44 | 6/8 | 5/15 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/6 | 11/36 | 7/10 | 2/10 | 12/40 | 9/45 | 1/11 | 11/44 | 2/8 | 3/15 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/6 | 12/36 | 4/10 | 2/10 | 16/40 | 18/45 | 5/11 | 12/44 | 5/8 | 6/15 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/3 | 1/6 | 6/36 | 0/10 | 2/10 | 5/40 | 12/45 | 1/11 | 11/44 | 5/8 | 3/15 |
| ConstipationGastrointestinal disorders | 1/4 | 0/3 | 0/6 | 7/36 | 1/10 | 4/10 | 14/40 | 17/45 | 3/11 | 12/44 | 5/8 | 7/15 |
| AstheniaGeneral disorders | 1/4 | 1/3 | 0/6 | 6/36 | 0/10 | 1/10 | 4/40 | 8/45 | 2/11 | 6/44 | 5/8 | 0/15 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/4 | 0/3 | 0/6 | 20/36 | 2/10 | 5/10 | 4/40 | 5/45 | 1/11 | 15/44 | 2/8 | 9/15 |
| Oedema peripheralGeneral disorders | 0/4 | 0/3 | 0/6 | 20/36 | 2/10 | 0/10 | 11/40 | 5/45 | 1/11 | 4/44 | 0/8 | 2/15 |
The Safety Analysis Set included all participants who received at least 1 infusion at any dose level of study drug (ADX).
| Age, Customized(Participants) | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age — < 65 years | 2 | 0 | 4 | 15 | 2 | 4 | 25 | 26 | 8 | 33 | 4 | 10 | 133 |
| Age — ≥ 65 years | 2 | 3 | 2 | 21 | 8 | 6 | 15 | 19 | 3 | 11 | 4 | 5 | 99 |
| Sex: Female, Male(Participants) | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 10 | 7 | 4 | 9 | 19 | 3 | 25 | 2 | 13 | 95 |
| Male | 3 | 3 | 4 | 26 | 3 | 6 | 31 | 26 | 8 | 19 | 6 | 2 | 137 |
| Race/Ethnicity, Customized(Participants) | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 0 | 4 | 0 | 1 | 4 | 4 | 0 | 4 | 0 | 2 | 19 |
| Ethnicity — Not Hispanic or Latino | 4 | 3 | 6 | 32 | 10 | 9 | 30 | 39 | 10 | 39 | 8 | 12 | 202 |
| Ethnicity — Not Permitted | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 2 | 1 | 1 | 0 | 1 | 11 |
| Race/Ethnicity, Customized(Participants) | Part A: ADX 200 mg | Part A: ADX 600 mg | Part A: ADX 1800 mg | Part B: PAC, ADX 800 mg | Part B: LAC, ADX 1200 mg | Part B: LSC, ADX 1200 mg | Part B: EGC, ADX 800 mg | Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg | Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg | Part B: BRCA, ADX 800 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 3 |
| Race — Asian | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 4 |
| Race — Black or African American | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 6 | 2 | 2 | 1 | 1 | 18 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race — White | 3 | 3 | 5 | 33 | 9 | 5 | 31 | 35 | 8 | 35 | 6 | 12 | 185 |
| Race — Not Permitted | 1 | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 0 | 2 | 0 | 1 | 13 |
| Race — Other | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2013 to primary completion in Apr 2019, 72 months.
Results were first posted in May 2020, 1 year after primary completion.
Of 171 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's 72 months is above that.
Counting every sponsor, half of 379 studies reached it within 45 months; a quarter within 32 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Andecaliximab